

ICSI has updated its guideline template and these changes are reflected in the current guideline.

Scope

The scope statement was fleshed out to reflect the guideline criteria for diagnosis of stable coronary artery disease, rather than referring the reader elsewhere.

Algorithms

No changes to the numbering of steps in the algorithm were made. References to ICSI's former stress test supplement were deleted due to its retirement.

Clinical Highlights

No changes were made.

Annotations

- * 5. Reference to Lichtman 2008 was added with recommendation that patients with stable CAD be routinely screened for and appropriately treated for depression.
Reference to Boucher 2008 was added with clarification that as little as 5%-10% weight loss has health benefits.
Reference to the ACCORD trial and reference to Skyler 2009 was added to address the ADA/ACC/AHA position on the ACCORD trial's implications for SCAD patients.
- * 20. Medical therapy was highlighted in its importance relative to interventional procedures for revascularization of the stable coronary artery disease patient. Medical interventions were suggested so the practitioner has practical "take-aways" from the Courage trial's findings.
- * 21b. A discussion of EPA, DHA, and ALA was expanded, including recommendations to counsel patients in proper interpretation of fish oil supplement labels to obtain the correct dose, referencing Lee 2008. Reference to Yokoyama 2007 JELIS trial was added, highlighting a 19% reduction in major coronary events after several years' treatment with EPA plus DHA supplement.
- * 21c. The EUROPA (2003) and HOPE (2000) studies were referenced along with Mann 2008 in an expanded discussion of ACE-inhibitors, noting that an adequate substitute would be angiotensin II receptor blockers.

Appendix B, Medication Tables, was reorganized to include a header "As needed – nitrates."

Appendix D, Omega-3 Fatty Acids, was revised.

Conclusion grading worksheets were deleted, as they reflect standard of care.

Priority Aims & Suggested Measures / Measurement Specifications

- Support for Implementation section was reorganized for clarity.

*An asterisk indicates any changes in clinical practice recommendations

- A section for key implementation recommendations was added to the guideline.
- Aims & Measures. Priority aims and suggested measures were revised as needed to correlate with clinical highlights.